Abstract
Forty patients with advanced renal cell carcinoma were treated with elliptinium by a weekly infusion of 100 mg/m2. Of 38 evaluable patients, five had an objective response (13.2%). Average response duration was 8 months (range, 5-11). The major dose-limiting toxic effect was induction of antielliptinium antibodies, with the risk of intravascular hemolysis. Elliptinium has modest activity in advanced renal cell cancer and does not produce myelosuppression.
MeSH terms
-
Adult
-
Aged
-
Alkaloids / therapeutic use*
-
Antibodies / analysis
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / immunology
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / secondary
-
Drug Evaluation
-
Ellipticines / adverse effects
-
Ellipticines / immunology
-
Ellipticines / therapeutic use*
-
Female
-
Humans
-
Kidney Neoplasms / drug therapy*
-
Male
-
Middle Aged
Substances
-
Alkaloids
-
Antibodies
-
Antineoplastic Agents
-
Ellipticines
-
elliptinium